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It has been a great privilege to serve as the 14th
President of the American Venous Forum. The presidents
of the forum have been such talented people that I have
wondered how I could be inducted into such an exclusive
club. Many people work very hard in the advancement of
the care of patients with venous and lymphatic disease, but
only a few are privileged to serve as president of the Amer-
ican Venous Forum. To all of you who have worked harder
than I, made greater contributions than I to the field of
venous disease, and contributed more to this organization
than I have but have not yet had the honor of this office, I
offer my apologizes, but not my hotel room; the presiden-
tial suite of this hotel is really very nice!
I would like to thank some of the people who have
helped me get to this podium. I know it is traditional to
thank your family, but I think it demeans the importance of
family to regard family as a vehicle to professional success.
There are many great families where success outside the
family has been limited. Personal relationships develop you
as a person not as a professional. Who you are is far more
important than what you are. I hope I am a better father
than doctor, although I admit that I put in more time being
a doctor than a father.
Mark Mattos, Tom Wakefield, Jim Menzoian, and
Robin Hoyle have combined to make my year as president
both efficient and enjoyable. Two of the five people who
had the greatest influence on the academic component of
my career have passed away in the last year. I am, of course,
speaking of John Porter and Gene Strandness. Both pro-
vided professional opportunity and, in their own ways,
encouragement. Opportunity is priceless. Professor
Bollinger is here today as my invited guest, another man
who provided me opportunity. Not here are Lloyd Taylor
and Rich Yeager, my senior partners in vascular surgery at
Oregon. They also have provided opportunity by putting
up with the inevitable hassles induced by my ever-changing
schedule and have been, and continue to be, advisors and
teachers. Early in my career, John Bergan went out of his
way to help me develop my interest in venous disease. Jim
Deweese, George Johnson, Lazar Greenfield, Jimmy Yao,
Bob Hobson, and Tom O’Donnell have been academic
surgeon role models. It has been a privilege to be associated
with these men through this organization.
I am not going to use slides for this talk. I observe that
heads of state do not use slides when they give an address.
Winston Churchill never used slides and managed to com-
municate reasonably well. No slides, however, is a bit of a
risk for me. I know I am no Sir Winston. I have given
hundreds of talks, but I have never given a talk without
slides. To hedge this risk, I will not speak for very long.
Although it is a great honor to be President of the
American Venous Forum, it is a great pain to prepare a
presidential address. No one has a lot of practice preparing
presidential addresses. Not that many come around each
year. Perhaps this is to the great relief of those who politely
sit and listen to them and a disappointment to those who
view a presidential address as an opportunity for a nap. I am
not even sure of the relevance of presidential addresses in
the modern world. At one time, a president of a society
could use a presidential address to update the membership
on a particular topic in which he or she was considered an
expert. Now all that information is readily available to
everyone on the computer. With a little effort, everyone can
know as much as the “expert.” A frequent approach is for
the presidents to use their presidential addresses to remi-
nisce about their careers and their impact on that society’s
particular field of interest. However, I am not sure I have
had all that much impact. My father used to remind me that
if I ever began to feel important that a walk though the
graveyard would put it all back in the proper perspective. I
certainly hope that at age 48 years I am less concerned with
what I have done than what I will do or with what I will be
privileged to help others accomplish. I do not think a
presidential address should be about data or a long refer-
ence list. I do believe a presidential address should be about
providing a message. The message should be simple.
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The title of my presentation may seem a bit strange
unless you are familiar with my family and are an avid reader
of the New Yorker magazine. Those of you who know me
understand that my family is utterly and totally devoted to
horses. They live, breathe, and talk about virtually nothing
but horses. All my money goes to horses. The needs of a
horse are without limits. My daughters wonder why they do
not have more dates, but even the most hormone-infused
teenage boy will balk at dating a girl who frequently smells
like Trigger. However, needless to say, as the father of three
teenage girls, I sometimes actually see this as an upside to
the horse habit.
Many years ago, given my family’s avocation, I was
struck by a cartoon that appeared in the New Yorker. The
cartoon depicted a small boy enthusiastically digging
through a large pile of horse manure. The boy’s enthusiasm
stemmed from the fact that he believed his shoveling efforts
would ultimately prove worthwhile as somewhere within
that large pile of horse manure there surely must be a pony.
That boy was clearly an optimist, a “the glass is half full”
person. I believe I am an optimist. Most of us who pursue a
career in medicine, especially an academic career, are fueled
by our optimism, our belief that our efforts make a differ-
ence and goals will ultimately be accomplished. Our reach
often exceeds our grasp and that is good; without goals,
effort is of no value. As the saying goes: “Those who believe
they can do something likely will. Those who believe they
cannot succeed are also likely to be correct.”
Two years ago at this meeting I was saddened by Sir
Norman Browse’s lecture as the invited guest of President
David Sumner. My impression was that the basic thesis of
Professor Browse’s presentation was a lack of progress in
the field of venous disease. Sir Norman’s lecture was, as
always and as expected, masterfully presented. My apolo-
gies to Professor Browse if I have misinterpreted his posi-
tion. However, from my perspective, it was too pessimistic,
a “the glass is half empty” position. I greatly admire Pro-
fessor Browse, his intellect, and his ability to speak extem-
poraneously; however, my view with respect to research in
venous disease differs from his. Perhaps this difference
reflects my relative inexperience versus Sir Norman’s savvy
acquired over a long and distinguished career. Perhaps it
reflects American optimism versus traditional British skep-
tism. Who knows?
To be fair, however, Professor Browse is not the only
skeptic. Often busy vascular surgeons in community prac-
tice subconsciously regard venous patients as mere fillers in
their arterial surgery schedule. Academically oriented vas-
cular surgeons are in many cases no better. Many members
of the Society for Vascular Surgery are not members of the
American Venous Forum. My guess, however, is that most
members of the Society for Vascular Surgery treat patients
with venous ulcers, lymph edema, and varicose veins. Even
my deceased partner, John Porter, himself a founding
member of this organization, also, late in his career, became
disillusioned with progress in the care of patients with
venous disease. John often questioned why with a busy
arterial surgery practice I remained interested in venous
problems. His point was that compression was the only
effective therapy for venous disease and that it did not take
a rocket scientist to prescribe elastic stockings.
I think, however, one should be driven not only by
what is cool, dramatic, and new. What helps is also very
important. I strongly suspect more actual patient-incurred
overall good has been achieved through the use of elastic
compression for chronic venous insufficiency than will ever
be achieved with endograft repair of 4-cm abdominal aortic
aneurysms. When things are examined closely, and one
does not focus only on the surgical aspects of venous
disorders, the last 40 years can truly be regarded as a period
of tremendous progress in venous research and in the care
of patients with venous disease.
How many thousands of patients have been spared the
life-long disability of chronic venous insufficiency through
the widespread use of deep venous thrombosis prophylaxis
in the perioperative period? How many lives have been
saved through such prophylaxis, anticoagulant treatment of
deep venous thrombosis, or the use of vena cava filters? I do
not pretend to know the number, but it must be in the
many thousands and surly dwarfs the number of lives saved
through prophylactic repair of thoracoabdominal aneu-
rysms and at a fraction of the per patient cost. How many
patients have benefitted through the use of and widespread
availability of elastic compression stockings to control the
effects of chronic venous insufficiency? Surely many tens of
thousands. How many deep venous thromboses have been
painlessly diagnosed without complication through the use
of venous duplex scanning? Hundreds of thousands is
probably not an exaggeration. Each year the coagulation
process is better understood. Our partners in industry have
spent millions of dollars in the search for better products for
the prevention, treatment, and diagnosis of venous disease.
Venous disease has become the primary focus of both some
pharmaceutical and biotechnology companies. Funding
agencies now recognize there are blood vessels other than
arteries.
One should also look at the progress of the American
Venous Forum. In less than 15 years, it has gone from
nonexistent to sponsoring the world’s premier meeting
devoted to venous disease. Through the generosity of
American Venous Forum industrial sponsors, the American
Venous Forum has funded significant research and helped
launch academic careers. With all due respect to Professor
Browse and the late Dr Porter, there has been progress in
venous disease and there is ample reason to believe more
progress will be made. A career in venous disease clinical or
laboratory research holds great promise for young investi-
gators willing to dedicate themselves to relieving suffering.
To illustrate this, consider venous ulceration. This is
the most vexing and frustrating problem in the care of
patients with venous disease. Venous ulceration is as old as
antiquity. Its basic treatment, bandages and compression,
has remained unchanged for hundreds of years. Compres-
sive therapy for venous ulceration is a great improvement
over no therapy for venous ulcer. But despite compression
therapy being the best available treatment for chronic ve-
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nous insufficiency and venous ulcer, it is still not very good
therapy. Healing can be prolonged. Median time to ulcer
healing is 3 months in some series and longer in others.
Most venous ulcers are healed by 6 months of appropriate
therapy, but some ulcers never heal. Treatment remains
palliative. Cure is an illusion. A “healed” venous ulcer is
really an ulcer in remission. Recurrence is always lurking.
Frequently noncompliant, often economically disadvan-
taged patients, with a life-long incurable disease are not the
things dreams are made of. Have any of you ever visited
Professor Bernand’s ulcer clinic at St Thomas’ Hospital in
London? A fascinating experience, but not a tourist desti-
nation.
Venous ulceration is what gives venous disease a bad
name. It is, however, in the care of patients with venous
ulcer where there is the greatest potential for future
progress in the field of venous and lymphatic diseases.
Wherever there is great need, there is great potential for
progress that will truly make a difference. The beginnings
of this progress I believe are already here but somewhat
unrecognized. It is perhaps akin to the apocryphal story of
the man unjustly imprisoned for years in a gloomy dungeon
who one day thought to push on the door only to find that
it was open and never had been locked.
The pathophysiology of venous insufficiency is com-
plex. The concept of one operation fits all is likely to lead to
disappointment. In this regard, the CEAP classification of
venous disease, tirelessly promoted by Dr Kistner, is a
recent major advance in the field of chronic venous insuffi-
ciency. Previous classification systems have been proposed,
but none have focused so extensively on the underlying
anatomic and physiologic abnormalities present in the in-
dividual patient. If we really do not know what we are
treating, it is difficult to assess the effectiveness of treat-
ment.
We also need to be able to identify which patients with
venous insufficiency are most likely to respond to surgical
therapies. This can only be done with detailed knowledge
of the patients anatomic and physiologic abnormalities. I
have a suspicion the best candidates will be patients prone
to development of a venous ulcer, not those patients who
actually have progressed to the point where the skin is so
badly damaged that an ulcer has developed. I know some of
you believe lipodermatosclerosis improves with proper
compression therapy or surgical therapy to relieve venous
hypertension. However, when all therapies for venous ulcer
are prone to high recurrence rates, it must be that if
improvement of lipodermatosclerosis occurs with any me-
chanical therapy, it is not much improvement. Given the
destruction of microcirculatory capillary and lymphatic
anatomy associated with lipodermatosclerosis, improve-
ment of lipodermatosclerosis should not, in my opinion, be
expected. Stabilization of lipodermatosclerosis may be the
best that can be expected with a surgical procedure. The
challenge becomes identifying who to treat surgically with
a prophylactic operation. Obviously, many patients
thought to be at risk for venous ulceration will need to be
well characterized and followed longitudinally to deter-
mine the characteristics of a population sufficiently at risk to
merit prophylactic surgery. CEAP should help with such
studies. It is rewarding to now see papers assessing the
utility of CEAP and to note more and more papers are
describing detailed duplex scan assessment of the veins
before procedures for chronic venous insufficiency.
The concept of combining anatomic and physiologic
assessment of the venous system to aid in preoperative
planning of procedures purported to improve venous he-
modynamics is also an advance in the care of patients with
chronic venous insufficiency and venous ulceration. All of
this is in its early stages. I do believe, however, the idea of
accurately describing the anatomic and physiologic abnor-
malities present in patients with chronic venous insuffi-
ciency and eventually tailoring intervention to the individ-
ual patient is a concept that is here to stay. Some day we will
no more think about doing an operation for venous disease
without sound preoperative and postoperative physiologic
assessment than we would today think about doing arterial
reconstructions without preoperative and postoperative an-
kle brachial index measurements. In my opinion, the genius
of Gene Strandness really had little to do with duplex
scanning or the wonderful natural history studies of arterial
and venous disease that have come out of the University of
Washington. The genius of Gene Strandness lay in recog-
nizing the importance of physiology in vascular disease, the
importance in understanding what you are treating and
assessing the physiologic results of that treatment.
Many details need to be filled in with respect to the
venous system, and many hypotheses remain to be tested.
Recognition of how much we do not know, an appreciation
of what needs to be done, and the acquisition of the proper
tools for research by interested and energetic people are all
important advances in venous research, especially with re-
spect to chronic venous insufficiency. Their importance lies
in the fact that they provide a framework for research, and
not just laboratory research. Laboratory research is impor-
tant and, I believe, will be the key to solving the problem of
venous ulceration. Ultimately, however, clinical rather than
bench research is what moves medicine forward. Young
investigators who are not inclined to laboratory research
can be assured that there is a place for them as well in
academic medicine. Gene Strandness never killed a single
rat.
We must recognize that venous ulceration is not a
disease of the veins but a disease of the skin and subcuta-
neous tissues induced by abnormalities in the veins. These
cutaneous abnormalities will not rapidly be cured with
elastic stockings, Linton procedures, vein stripping, subfas-
cial endoscopic perforator surgery, or all the stents and
angioplasty balloons in the Western world. We need to
recognize that the cause of the disease should not be the
only focus of the cure of the disease. Certainly, cigarette
smoking causes many lung cancers. No existing lung can-
cer, however, is ever cured by stopping smoking. This is not
to say we should not continue our efforts to find effective
surgical and nonsurgical treatments to alleviate the venous
hypertension that leads to the cutaneous changes that
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ultimately lead to venous ulceration. I do think, however,
we are a bit ahead of ourselves in trying to develop surgical
cures for venous hypertension without first determining
which patients are most likely to benefit. The approach of
operating on everyone and then seeing who benefits seems
inefficient and is likely to do more to obscure than to reveal
truth. It is, however, the typical and traditional surgical
approach. When was the last time any surgeon read an
instruction book before beginning a project?
Venous ulceration induces a constellation of cellular
and anatomic cutaneous abnormalities that combine to
produce a venous ulcer. Many of these changes were de-
scribed earlier by Professor Bollinger in his guest lecture.
These observations are in many cases preliminary but are
clearly of interest and the potential focus of extensive future
research.
For example, cutaneous capillary endothelial cells are
morphologically and functionally changed in chronic ve-
nous insufficiency. A low-grade endothelial injury appears
to exist. The endothelial cells have an irregular surface with
more pinocytotic vesicles and a widening of the endothelial
space. These changes suggest endothelial injury as a conse-
quence of venous insufficiency. Endothelial cells subject to
chronic venous insufficiency also appear to have increased
production of endothelial cell activation markers, such as
intracellular adhesion molecule-1, vascular adhesion mole-
cule-1, and interleukin-1. Lymphocyte and monocyte infil-
tration into the skin of patients with chronic venous insuf-
ficiency also suggests a proinflammatory response is part of
the pathophysiology of venous ulceration. Whether or not
this proinflammatory response can be modulated in pa-
tients with chronic venous insufficiency and whether or not
it may be important to do so is completely unknown.
The pathophysiology of the dermal fibroblast dysfunc-
tion and the cutaneous fibrosis so characteristic of severe
chronic venous insufficiency is only beginning to be studied
with modern biochemical techniques. Some of this work
has been funded through research grants administered
through the American Venous Forum. Peter Pappas and his
colleagues in New Jersey have investigated the role of
TGF-1 in the dermal tissue fibrosis that accompanies
chronic venous insufficiency. Thus far TGF-1 is the only
cytokine found to be important in stasis dermatitis and the
lipodermatosclerosis of chronic venous insufficiency.
Whether or not other cytokines can be modulated to im-
prove venous ulcer healing or slow down the lipodermato-
sclerosis of chronic venous insufficiency remains to be
determined.
It is clear that cytokines and growth factors produced
by cutaneous tissues can be delivered to a venous ulcer
through the use of bioengneered skin substitutes. At least
two companies now have US Food and Drug Administra-
tion-approved bioengineered skin substitutes that produce
a spectrum of growth factors and cytokines thought to be
important in healing of cutaneous wounds. The ability of
these growth factors to stimulate fibroblasts associated with
chronic venous ulcers is uncertain. Studies, some sponsored
by the American Venous Forum, have shown fibroblasts
isolated from chronic venous ulcers are phenotypically dif-
ferent and behave differently in response to growth factors
than fibroblasts isolated from other sites. Compared with
normal fibroblasts, those from venous ulcers are larger and
more polygonal, with extensive variations in the morphol-
ogy of the nucleus. Such changes are thought to be associ-
ated with senescent cells with the implication that some
aspect of wound physiology induced by venous ulceration
promotes cellular senescence and therefore impairs healing
of the ulcer. Indeed, it appears that the growth rates of
fibroblasts cultured from venous ulcers are less than ex-
pected when these fibroblasts are stimulated with basic
fibroblast growth factor and epidermal growth factor. It
may be that while bioengneered materials can be manufac-
tured to deliver growth factors to venous ulcers, these
growth factors may be largely ineffective unless some way
can be found to stimulate the responsiveness of the ulcer
cells to the presence of the growth factors.
From my perspective all this uncertainty is not the
source of discouragement but the basis of excitement. We
do not have all the answers, but we do have some answers,
and more importantly, we have some new questions and we
are gradually attracting individuals with the skills to address
these questions. It is my hope that the presidency of this
society will, in the future, be bestowed consistently on
those who perform well-designed prospective clinical trials
and engage in state-of-the-art basic research. Such individ-
uals will not have to struggle with the relevance of their
contributions to venous disease. Such people will always be
seeking to move forward. They will realize there is a long
way to go but that we have also come a great distance. They
will be optimists, and the patients will benefit.
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